Safety and Efficacy of Radioimmunotherapy with 90Yttrium-rituximab in Patients with Relapsed CD20+ B cell Lymphoma: A Feasibility Study

M. Vaes; D. Bron; D.J. Vugts; M. Paesmans; M. Meuleman; G. Ghanem; T. Guiot; B. Vanderlinden; K. Thielemans; G.A.M.S. van Dongen; P. Flamen; K. Muylle

doi:10.4172/1948-5956.1000173

Safety and Efficacy of Radioimmunotherapy with 90Yttrium-rituximab in Patients with Relapsed CD20+ B cell Lymphoma: A Feasibility Study

M. Vaes, D. Bron, D.J. Vugts, M. Paesmans, M. Meuleman, G. Ghanem, T. Guiot, B. Vanderlinden, K. Thielemans, G.A.M.S. van Dongen, P. Flamen, K. Muylle

Research output: Contribution to journal › Article › Academic

93 Downloads (Pure)

Original language	English
Pages (from-to)	394-400
Journal	Journal of Cancer Science & Therapy
Volume	4
Issue number	12
DOIs	https://doi.org/10.4172/1948-5956.1000173
Publication status	Published - 2012

Access to Document

10.4172/1948-5956.1000173

303906Final published version, 1.52 MB

http://omicsonline.org/safety-and-efficacy-of-radioimmunotherapy-with-yttriumrituximab-in-patients-1948-5956.1000173.pdf

Cite this

Vaes, M., Bron, D., Vugts, D. J., Paesmans, M., Meuleman, M., Ghanem, G., Guiot, T., Vanderlinden, B., Thielemans, K., van Dongen, G. A. M. S., Flamen, P., & Muylle, K. (2012). Safety and Efficacy of Radioimmunotherapy with 90Yttrium-rituximab in Patients with Relapsed CD20+ B cell Lymphoma: A Feasibility Study. Journal of Cancer Science & Therapy, 4(12), 394-400. https://doi.org/10.4172/1948-5956.1000173

Vaes, M. ; Bron, D. ; Vugts, D.J. ; Paesmans, M. ; Meuleman, M. ; Ghanem, G. ; Guiot, T. ; Vanderlinden, B. ; Thielemans, K. ; van Dongen, G.A.M.S. ; Flamen, P. ; Muylle, K. / Safety and Efficacy of Radioimmunotherapy with 90Yttrium-rituximab in Patients with Relapsed CD20+ B cell Lymphoma: A Feasibility Study. In: Journal of Cancer Science & Therapy. 2012 ; Vol. 4, No. 12. pp. 394-400.

@article{b577440e752d4dcd8b8a2a18eabcb78c,

title = "Safety and Efficacy of Radioimmunotherapy with 90Yttrium-rituximab in Patients with Relapsed CD20+ B cell Lymphoma: A Feasibility Study",

author = "M. Vaes and D. Bron and D.J. Vugts and M. Paesmans and M. Meuleman and G. Ghanem and T. Guiot and B. Vanderlinden and K. Thielemans and {van Dongen}, G.A.M.S. and P. Flamen and K. Muylle",

year = "2012",

doi = "10.4172/1948-5956.1000173",

language = "English",

volume = "4",

pages = "394--400",

journal = "Journal of Cancer Science & Therapy",

issn = "1948-5956",

publisher = "OMICS Publishing Group",

number = "12",

}

Vaes, M, Bron, D, Vugts, DJ, Paesmans, M, Meuleman, M, Ghanem, G, Guiot, T, Vanderlinden, B, Thielemans, K, van Dongen, GAMS, Flamen, P & Muylle, K 2012, 'Safety and Efficacy of Radioimmunotherapy with 90Yttrium-rituximab in Patients with Relapsed CD20+ B cell Lymphoma: A Feasibility Study', Journal of Cancer Science & Therapy, vol. 4, no. 12, pp. 394-400. https://doi.org/10.4172/1948-5956.1000173

Safety and Efficacy of Radioimmunotherapy with 90Yttrium-rituximab in Patients with Relapsed CD20+ B cell Lymphoma: A Feasibility Study. / Vaes, M.; Bron, D.; Vugts, D.J.; Paesmans, M.; Meuleman, M.; Ghanem, G.; Guiot, T.; Vanderlinden, B.; Thielemans, K.; van Dongen, G.A.M.S.; Flamen, P.; Muylle, K.

In: Journal of Cancer Science & Therapy, Vol. 4, No. 12, 2012, p. 394-400.

Research output: Contribution to journal › Article › Academic

TY - JOUR

T1 - Safety and Efficacy of Radioimmunotherapy with 90Yttrium-rituximab in Patients with Relapsed CD20+ B cell Lymphoma: A Feasibility Study

AU - Vaes, M.

AU - Bron, D.

AU - Vugts, D.J.

AU - Paesmans, M.

AU - Meuleman, M.

AU - Ghanem, G.

AU - Guiot, T.

AU - Vanderlinden, B.

AU - Thielemans, K.

AU - van Dongen, G.A.M.S.

AU - Flamen, P.

AU - Muylle, K.

PY - 2012

Y1 - 2012

U2 - 10.4172/1948-5956.1000173

DO - 10.4172/1948-5956.1000173

M3 - Article

VL - 4

SP - 394

EP - 400

JO - Journal of Cancer Science & Therapy

JF - Journal of Cancer Science & Therapy

SN - 1948-5956

IS - 12

ER -